<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2510234394
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1996
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NIMOTOP 30MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NIMODIPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nimotop tablets contains nimodipine, which belongs to a group of<br />medicines called calcium antagonists.<br /><strong>Nimotop tablets are used to prevent changes in brain function</strong><br />after bleeding around the brain (subarachnoid haemorrhage).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Nimotop</strong></p><p><strong>▸ At the same time as you are getting Nimotop solution<br />through a drip</strong>. The tablets have been prescribed as a<br />convenient way to continue your treatment after the drip is<br />stopped.<br /><strong>▸ If you have had a heart attack</strong> within the last month.<br /><strong>▸ If you suffer from angina</strong> and notice an increase in the<br />frequency and severity of attacks.<br /><strong>▸ If you are allergic to nimodipine</strong> or any of the ingredients of<br />this medicine (listed in section 6).<br /><strong>▸ If you are taking rifampicin</strong> (an antibiotic), phenobarbital,<br />phenytoin or carbamazepine (three medicines most<br />commonly used to treat epilepsy).<br /><strong>&rarr; Tell your doctor and do not take Nimotop tablets </strong>if any of<br />these apply to you.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Nimotop tablets<br /><strong>▸ If you had a head injury,</strong> which caused bleeding around the<br />brain (traumatic subarachnoid haemorrhage).<br /><strong>▸ If you have fluid in the brain or severely raised pressure in<br />your skull.</strong> Your doctor will be able to advise you about this.<br /><strong>▸ If you have low blood pressure</strong>.<br /><strong>▸ If you have liver disease.</strong> You will probably need to have your<br />blood pressure measured regularly.</p><p><strong>&rarr; Tell your doctor before you take Nimotop tablets,</strong> if any of<br />these apply to you.<br /><strong>Children and adolescents</strong><br />Do not give Nimotop tablets to children under the age of 18 as the<br />safety and efficacy of Nimotop have not been established.<br /><strong>Other medicines and Nimotop tablets</strong><br />You will not be given Nimotop tablets if you are receiving Nimotop<br />Solution.<br />You are not to be given rifampicin (an antibiotic), phenobarbital,<br />phenytoin, or carbamazepine (anti-epileptic drugs) if you are<br />taking Nimotop tablets.<br />Tell your doctor if you are taking, have recently taken or might<br />take any other medicines.<br />Some medicines may affect the way Nimotop tablets works. Tell<br />your doctor if you are taking:<br /><strong>▸</strong> High blood pressure tablets (including nifedipine, diltiazem,<br />verapamil, alphamethyldopa, alpha-blockers or beta-blockers).<br />Nimotop tablets may increase the effect of these medicines.<br /><strong>▸</strong> An <strong>anti-ulcer </strong>drug called cimetidine or an anti-epilepsy drug<br />called sodium valproate. These medicines may increase the<br />effect of Nimotop tablets.<br /><strong>▸</strong> The anti-depressant drugs fluoxetine or nefazodone.<br /><strong>▸</strong> The <strong>anti-HIV</strong> drug zidovudine (AZT).<br /><strong>▸</strong> The <strong>HIV protease inhibitor drugs</strong> indinavir, ritonavir,<br />nelfinavir or saquinavir.<br /><strong>▸</strong> The antibiotic erythromycin or the anti-fungal drugs<br />ketoconazole, itraconazole or fluconazole.<br /><strong>▸</strong> The antibiotic drug combination quinupristin / dalfopristin.<br /><strong>Nimotop tablets with food and drink</strong><br />You can take Nimotop tablets with or without food.<br /><strong>Do not drink grapefruit juice or eat grapefruit while taking<br />Nimotop tablets.</strong><br />Do not start taking Nimotop tablets within 4 days of drinking<br />grapefruit juice or eating grapefruit. Tell your doctor if you have<br />had grapefruit or grapefruit juice in this time. Also, do not drink<br />grapefruit juice or eat grapefruit whilst taking Nimotop tablets.<br />Grapefruit juice is known to increase the blood levels of the active<br />ingredient, nimodipine. This effect can last for at least four days.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant, think you may be pregnant or are planning to<br />have a baby, ask your doctor for advice before taking this medicine.<br />Follow his/her instructions carefully.<br /><strong>Do not breast-feed while taking Nimotop tablets.<br />If you are trying to father a child,</strong> talk to your doctor. Medicines<br />like Nimotop tablets can sometimes affect male fertility.<br />Driving and using machines<br />Nimotop tablets may make you feel dizzy. Do not drive or operate<br />machinery if you are affected in this way.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you.<br />Check with your doctor or pharmacist if you are not sure.<br /><strong>▸ The recommended dose </strong>is 2 tablets, every four hours, this<br />gives a maximum daily dose of 12 tablets (360 mg).<br /><strong>▸ Keep taking the tablets for as long as your doctor has told<br />you </strong>to. This may be for up to 21 days.</p><p>Swallow the tablets with a little water.<br /><strong>Do not take more than your doctor has prescribed.<br />If you take more Nimotop tablets than you should<br />&rarr; Get medical help immediately</strong> and, if possible, take your<br />tablets with you. Taking too much Nimotop tablets may cause<br />low blood pressure (you may feel faint), heartbeats that are<br />faster or slower than usual and feeling sick.<br /><strong>If you forget to take the tablets</strong><br />Take your normal dose immediately and carry on taking that day&rsquo;s<br />tablets at 4-hour intervals.<br />Do not take a double dose to make up for the forgotten tablets.<br />If you have any further questions on the use of this medicine, ask<br />your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although<br />not everybody gets them.<br /><strong>Potentially serious side effects<br />If you experience:</strong><br /><strong>▸</strong> Signs of allergic reaction such as swelling of the face, lips,<br />tongue or throat, difficulty breathing, rash, itching, nausea or<br />vomiting<br /><strong>▸</strong>low blood pressure (may cause dizziness)<br /><strong>▸</strong>slow heartbeat<br /><strong>▸</strong> easier bruising and bleeding caused by a reduced number of<br />blood platelets<br /><strong>&rarr; Contact your doctor immediately as these side effects can<br />sometimes be serious.</strong><br /><strong>Less serious side effects</strong><br />In addition to the serious side effects listed above, these are the<br />other less serious side effects of Nimotop tablets:<br /><strong>Uncommon side effects:</strong> (These may affect less than 1 in 100<br />people)<br /><strong>▸</strong> rash<br /><strong>▸</strong> headache<br /><strong>▸</strong> fast heartbeat<br /><strong>▸</strong> flushing, sweating, feeling of warmth<br /><strong>▸</strong> feeling sick (nausea)<br /><strong>Rare side effects:</strong> (These may affect less than 1 in 1,000 people)<br /><strong>▸</strong> constipation (lack of bowel movement)<br /><strong>▸</strong> slight rise in liver enzymes (this will show up in blood tests)<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or pharmacist. This<br />includes any possible side effects not listed in this leaflet. By<br />reporting side effects, you can help provide more information on<br />the safety of this medicine.<br /><strong>To report any side effect(s):</strong><br />The National Pharmacovigilance Centre (NPC).<br />SFDA call center: 19999.<br />E - mail: npc.drug@sfda.gov.sa.<br />Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine out of the sight and reach of children.</strong><br />Not to be stored above 25&deg;C.<br />Do not use this medicine after the expiry date which is stated on<br />both the outer carton and on each blister strip of tablets after EXP.<br />The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household<br />waste. Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is nimodipine. Each film-coated tablet<br />contains 30 mg of nimodipine.<br />The other ingredients are microcrystalline cellulose,<br />hypromellose, macrogol, maize starch, povidone, crospovidone,<br />magnesium stearate and the colourings titanium dioxide (E171)<br />and iron oxide yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ▸ Nimotop tablets are film-coated tablets. The tablets are
yellow, round biconvex tablets with “SK” marked on one side
and the Bayer cross marked on the other side.
▸ Nimotop is available in blisters in a pack of 30 tablets.
The tablets come in boxes of 100, but your doctor will prescribe as
many as you need.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer and Marketing<br />Authorisation Holder:</strong><br />Bayer AG<br />Kaiser-Wilhelm-Allee 1<br />51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">تحتوي أقراص نيموتوب على نيموديبين، الذي ينتمي إلى مجموعة من الأدوية تسمى<em> مضادات الكالسيوم.</em></p><p dir="RTL" style="text-align:right"><strong>تستخدم أقراص نيموتوب لمنع التغييرات في وظائف المخ</strong> بعد اصابته بنزيف حول الدماغ (<em>نزيف تحت العنكبوتية</em>).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>لا تتناول أقراص نيموتوب</strong></p><p dir="RTL" style="text-align:right"><strong>في نفس الوقت الذي تستخدم فيه محلول نيموتوب من خلال التسريب بالتنقيط</strong>. لقد تم وصف الأقراص باعتبارها وسيلة ملائمة لمواصلة العلاج بعد إيقاف التسريب بالتنقيط.</p><p dir="RTL" style="text-align:right"><strong>إذا تم إصابتك بنوبة قلبية</strong> خلال الشهر الماضي.</p><p dir="RTL" style="text-align:right"><strong>إذا كنت تعاني من الذبحة الصدرية</strong> ولاحظت وجود زيادة في تكرار و شدة النوبات.</p><p dir="RTL" style="text-align:right"><strong>إذا كان لديك حساسية من النيموديبين</strong> أو من أي من المكونات في هذا المنتج (مذكورة في الجزء 6).</p><p dir="RTL" style="text-align:right"><strong>إذا كنت تتناول ريفامبيسين (مضاد حيوي)</strong>، الفينوباربيتال، الفينيتوين أو كربمزبين (معظم استخدامات الأدوية الثلاثة لعلاج الصرع).</p><p dir="RTL" style="text-align:right"><strong>ابلغ طبيبك ولا تتناول أقراص نيموتوب</strong> إذا كان أي من هذه الحالات ينطبق عليك.</p><p dir="RTL" style="text-align:right"><strong>التحذيرات و الإحتياطات</strong></p><p dir="RTL" style="text-align:right">تكلم مع طبيبك أو الصيدلي قبل تناول نيموتوب</p><p dir="RTL" style="text-align:right"><strong>إذا كان لديك إصابة في الرأس</strong>، التي تسبب النزيف حول الدماغ (<em>صدمة نزيف تحت العنكبوتية</em>).</p><p dir="RTL" style="text-align:right"><strong>إذا كان لديك سوائل في المخ أو ارتفاع شديد للضغط في الجمجمة.</strong>سوف يكون طبيبك قادر على تقديم النصح حول هذا الموضوع.</p><p dir="RTL" style="text-align:right"><strong>إذا كان لديك ضغط دم منخفض</strong>.</p><p dir="RTL" style="text-align:right"><strong>إذا كان لديك مرض في الكبد.</strong> سوف تحتاج على الأرجح أن يقاس ضغط دمك بانتظام.</p><p dir="RTL" style="text-align:right"><strong>ابلغ طبيبك قبل أن تتناول أقراص نيموتوب</strong>، إذا كان ينطبق عليك أي من هذه الحالات.</p><p><strong>الأطفال والمراهقين</strong></p><p dir="RTL" style="text-align:right">لا تعطي أقراص نيموتوب للأطفال الذين تقل أعمارهم عن 18 عامًا حيث لم يتم إثبات سلامة وفعالية نيموتوب.</p><p dir="RTL" style="text-align:right"><strong>الأدوية الأخرى و أقراص نيموتوب</strong></p><p dir="RTL" style="text-align:right">لن يوصف لك أقراص نيموتوب إذا كنت تستخدم<strong> محلول نيموتوب.</strong></p><p dir="RTL" style="text-align:right"><strong>لا يمكنك أن تتناول ريفامبيسين</strong> (مضاد حيوي)،<strong> الفينوباربيتال، الفينيتوين، أو كربمزبين </strong>(الأدوية المضادة للصرع)، إذا كنت تتناول أقراص نيموتوب.</p><p dir="RTL" style="text-align:right"><strong>أخبر طبيبك</strong> إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى</p><p dir="RTL" style="text-align:right">بعض الأدوية قد تؤثر على الطريقة التي تعمل بها أقراص نيموتوب.</p><p dir="RTL" style="text-align:right"><strong>ابلغ طبيبك</strong> إذا كنت تتناول أحد الأدوية الآتية:</p><p dir="RTL" style="text-align:right"><strong>أقراص علاج ارتفاع ضغط الدم</strong> (بما في ذلك نيفيديبين، ديلتيازيم، فيراباميل، ألفا ميثيل دوبا، محاصرات ألفا أو<strong> محاصرات بيتا</strong>). قد تسبب أقراص نيموتوب لزيادة تأثير هذه الأدوية.</p><p dir="RTL" style="text-align:right">دواء <strong>مضاد للقرحة</strong> يسمى <strong>السيميتيدين</strong> أو دواء <strong>مضاد للصرع </strong>يسمى<strong> فالبروات الصوديوم.</strong></p><p dir="RTL" style="text-align:right">يمكن لهذه الأدوية أن تزيد من تأثير أقراص نيموتوب.</p><p dir="RTL" style="text-align:right">الأدوية المضادة للاكتئاب أو فلوكستين أو نفاذودون.</p><p dir="RTL" style="text-align:right">أدوية<strong> لمكافحة فيروس نقص المناعة البشرية (</strong><strong>HIV</strong><strong>) زيدوفودين </strong>(AZT).</p><p dir="RTL" style="text-align:right">أدوية<strong> مثبطة لإنزيم البروتياز</strong> الخاص بفيروس نقص المناعة البشرية (HIV) اندينافير، ريتونافير، نلفينافير أو ساكوينافير.</p><p dir="RTL" style="text-align:right">المضاد الحيوي الاريثروميسين أو الأدوية المضادة للفطريات الكيتوكونازول، الايتراكونازول أو فلوكونازول.</p><p dir="RTL" style="text-align:right">دواء مضاد حيوي مركب من كوينوبرستين / دلفوبرستين.</p><p dir="RTL" style="text-align:right"><strong>أقراص نيموتوب مع الطعام و الشراب</strong></p><p dir="RTL" style="text-align:right">يمكن تناول أقراص نيموتوب مع أو بدون الطعام.</p><p dir="RTL" style="text-align:right"><strong>لا تشرب عصير جريب فروت أو تأكل الجريب فروت أثناء تناول أقراص نيموتوب.</strong></p><p dir="RTL" style="text-align:right">لا تبدأ بتناول أقراص نيموتوب في غضون 4 أيام من شرب عصير جريب فروت أو من أكل الجريب فروت.</p><p dir="RTL" style="text-align:right">ابلغ طبيبك إذا كان تناولت جريب فروت أو عصير جريب فروت في هذا الوقت.</p><p dir="RTL" style="text-align:right">أيضاً، لا تشرب عصير جريب فروت أو تأكل الجريب فروت، أثناء تناول أقراص نيموتوب.</p><p dir="RTL" style="text-align:right">من المعروف أن عصير جريب فروت يسبب زيادة لمستويات الدم للمادة الفعالة نيموديبين.</p><p dir="RTL" style="text-align:right">يمكن لهذا التأثير أن يستمر لمدة أربعة أيام على الأقل.</p><p dir="RTL" style="text-align:right"><strong>الحمل، الرضاعة الطبيعية و الخصوبة</strong></p><p dir="RTL" style="text-align:right"><strong>إذا كنت حاملاً</strong> ، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء. اتبع تعليماته / تعليماتها بعناية.</p><p dir="RTL" style="text-align:right"><strong>لا ترضعي</strong> أثناء تناول أقراص نيموتوب.</p><p dir="RTL" style="text-align:right"><strong>إذا كنت تحاول أن تصبح أب لطفل</strong> تحدث مع الطبيب. يمكن لأدوية مثل أقراص نيموتوب أن يكون لديها تأثير أحياناً على خصوبة الذكور.</p><p dir="RTL" style="text-align:right"><strong>القدرة على القيادة و تشغيل الماكينات</strong></p><p dir="RTL" style="text-align:right">قد تجعلك أقراص نيموتوب أن تشعر بالدوار.</p><p dir="RTL" style="text-align:right">يجب عدم القيادة أو تشغيل الماكينات إذا كنت تعاني من هذه الحالة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">إحرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL" style="text-align:right"><strong>الجرعة الموصى بها </strong>هي 2 حبة، كل أربع ساعات، وهذا يعطي الجرعة اليومية القصوى و هي 12 قرص (360 ميليغرام).</p><p dir="RTL" style="text-align:right"><strong>حافظ على تناول الأقراص ما دام طبيبك قد أبلغك بذلك. </strong>قد يكون ذلك لمدة قد تصل إلى 21 يوماً.</p><p dir="RTL" style="text-align:right">يتم بلع الأقراص مع قليل من الماء.</p><p dir="RTL" style="text-align:right"><strong>لا تتناول أكثر من الذي وصفه طبيبك.</strong></p><p dir="RTL" style="text-align:right"><strong>إذا تناولت أقراص نيموتوب أكثر مما ينبغي</strong></p><p dir="RTL" style="text-align:right"><strong>يتم الحصول على المساعدة الطبية فوراً،</strong> وإذا أمكن، تأخذ الأقراص معك. تناول الكثير من نيموتوب قد يسبب انخفاض ضغط الدم (قد تشعر بالإغماء)، دقات القلب تصبح أسرع أو أبطأ من المعتاد والشعور بالغثيان<strong>.</strong></p><p dir="RTL" style="text-align:right"><strong>إذا كنت قد نسيت أن تتناول الأقراص</strong></p><p dir="RTL" style="text-align:right">تناول الجرعة العادية على الفور، واستمر في تناول أقراص ذلك اليوم كل 4 ساعات كفترات زمنية فاصلة. لا تتناول جرعة مضاعفة للتعويض عن الأقراص المنسية.</p><p dir="RTL" style="text-align:right">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL" style="text-align:right"><strong>الآثار الجانبية التي يحتمل أن تكون خطيرة</strong></p><p dir="RTL" style="text-align:right"><strong>إذا عانيت من الآتي:</strong></p><p dir="RTL" style="text-align:right">علامات رد فعل تحسسي مثل تورم الوجه، الشفتين، اللسان أو الحلق، صعوبة في التنفس، طفح جلدي، حكة، غثيان أو قيء</p><p dir="RTL" style="text-align:right">انخفاض لضغط الدم (يمكن أن يسبب دوخة)</p><p dir="RTL" style="text-align:right">بطء ضربات القلب</p><p dir="RTL" style="text-align:right">سهولة حدوث كدمات و نزف ناجم عن انخفاض عدد الصفائح الدموية</p><p dir="RTL" style="text-align:right"><strong>ابلغ طبيبك فوراً لأن هذه الآثار الجانبية يمكن أن تكون أحياناً خطيرة.</strong></p><p dir="RTL" style="text-align:right"><strong>آثار جانبية أقل خطورة</strong></p><p dir="RTL" style="text-align:right">بالإضافة إلى الآثار الجانبية الخطيرة المذكورة أعلاه لأقراص نيموتوب، هذه هي الآثار الجانبية الأخرى الأقل خطورة:</p><p dir="RTL" style="text-align:right"><strong>الآثار الجانبية الغير شائعة </strong>(<em>يمكن أن تصيب أقل من 1 في 100 شخص</em>)</p><p dir="RTL" style="text-align:right">طفح جلدي</p><p dir="RTL" style="text-align:right">صداع</p><p dir="RTL" style="text-align:right">ضربات قلب سريعة</p><p dir="RTL" style="text-align:right">احمرار الوجه، التعرق، الشعور بالدفء</p><p dir="RTL" style="text-align:right">الشعور المرضي (الغثيان)</p><p dir="RTL" style="text-align:right"><strong>الآثار الجانبية النادرة </strong>(<em>يمكن أن تصيب أقل من 1 في 1000 شخص</em>)</p><p dir="RTL" style="text-align:right">الإمساك (عدم وجود حركة الامعاء)</p><p dir="RTL" style="text-align:right">ارتفاع طفيف في إنزيمات الكبد (سوف يظهر ذلك في فحوصات الدم)</p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="text-align:right">اذا تم إصابتك بأي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. هذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكن أن يساعد التبليغ عن الآثار الجانبية على توفير مزيد من المعلومات حول سلامة هذا الدواء</p><p dir="RTL" style="text-align:right"><strong>للإبلاغ عن أي أعراض جانبية</strong></p><p dir="RTL" style="text-align:right">المركز الوطني للتيقظ الدوائي</p><p dir="RTL" style="text-align:right">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL" style="text-align:right">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</strong></p><p dir="RTL" style="text-align:right">يحفظ عند درجة لا تزيد عن 25 درجة مئوية.</p><p dir="RTL" style="text-align:right">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على كل من العلبة الخارجية وعلى شريط الأقراص بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL" style="text-align:right">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">المادة الفعالة هي نيموديبين. يحتوي كل قرص مغلف على 30 ميليغرام نيموديبين.</p><p dir="RTL" style="text-align:right">المكونات الأخرى هي سليلوز ذو بلورات مجهرية، هيبرومللوز، ماكروجول، نشاء الذرة، بوفيدون، كروسبوفيدون، ستيارات الماغنيسيوم و الملونات ثنائي أكسيد التيتانيوم E 171 و أكسيد الحديد الأصفر E 172.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص نيموتوب هي أقراص مغلفة. الأقراص صفراء، مستديرة محدبة السطحين موسومة على أحد الجوانب ب &laquo;SK&raquo; و &laquo;علامة Bayer&raquo; على الجانب الآخر.</p><p dir="RTL" style="text-align:right">نيموتوب متوفر فى شرائط داخل عبوة تحتوي على 30 قرص مغلف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">باير ايه جي</p><p dir="RTL" style="text-align:right">قيصر-ويلهلم-آلي 1</p><p dir="RTL" style="text-align:right">51368 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2017.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nimotop 30mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 30 mg nimodipine.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Yellow, round biconvex tablets with “SK” marked on one side and the Bayer cross marked on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nimodipine is indicated for the prevention of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><strong><em>Aneurysmal subarachnoid haemorrhage:</em></strong></p><p><strong>Prophylactic administration - Adults</strong></p><p>The recommended dose is two tablets at 4-hourly intervals (total daily dose 360 mg) to be taken with water. Prophylactic administration should commence within four days of onset of subarachnoid haemorrhage and should be continued for 21 days.</p><p>In the event of surgical intervention, administration of Nimotop tablets should be continued (dosage as above) to complete the 21 days treatment period.</p><p>In patients who develop adverse reactions the dose should be reduced as necessary or the treatment discontinued</p><p><strong><em>Traumatic subarachnoid haemorrhage:</em></strong></p><p>Not recommended as a positive benefit to risk ratio has not been established (see section 4.4)</p><p><strong>Special populations:</strong></p><p><em>Patients with hepatic impairment</em></p><p>Severely disturbed liver function, particularly liver cirrhosis, may result in an increased bioavailability of nimodipine due to a decreased first-pass capacity and a reduced</p><p>metabolic clearance. The effects and side-effects, e.g. reduction in blood pressure, may be more pronounced in these patients.</p><p>In such cases, the dose should be reduced (depending on the blood pressure) or, if necessary, discontinuation of the treatment should be considered.</p><p>Upon co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers a dose adaption may be necessary (see section 4.5).</p><p><em>Elderly </em></p><p>There are no special dosage requirements for use in the elderly.</p><p><em>Paediatric population </em></p><p>The safety and efficacy of Nimotop in patients under 18 years of age have not been established.</p><p><u>Method of administration</u></p><p>In general, the tablets should be swallowed whole with a little liquid, with or without food. The interval between successive doses must not be less than 4 hours.</p><p>Grapefruit juice is to be avoided (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nimodipine must not be administered in case of hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Nimodipine should not be administered to patients during or within one month of a myocardial infarction or an episode of unstable angina.
The use of nimodipine in combination with rifampicin or the antiepileptic drugs, phenobarbital, phenytoin or carbamazepine is contraindicated as the efficacy of Nimotop tablets could be significantly reduced when concomitantly administered. (See section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nimotop should not be used in patients with traumatic subarachnoid haemorrhage as a positive benefit to risk ratio has not been established and the specific patient groups that might benefit cannot be identified for this indication.</p><p>Nimotop tablets should be used with care when cerebral oedema or severely raised intracranial pressure is present. Although treatment with Nimotop has not been shown to be associated with increases in intracranial pressure, close monitoring is recommended in these cases or when the water content of the brain tissue is elevated (generalised cerebral oedema).</p><p>Caution is required in patients with hypotension (systolic blood pressure lower than 100 mm Hg).</p><p>Decreased drug clearance may occur in cirrhotic patients receiving Nimotop and, therefore, close monitoring of blood pressure is recommended in these patients.</p><p>Nimodipine is metabolised via the cytochrome P450 3A4 system. Drugs that are known to either inhibit or induce this enzyme system may, therefore, alter the first pass or the clearance of nimodipine (see section 4.5&rdquo; and section 4.2 &ndash; &nbsp;<em>&ldquo;Patients with hepatic impairment</em>&rdquo;).</p><p>Drugs which are known inhibitors of the cytochrome P450 3A4 system and, therefore, may lead to increased plasma concentrations of nimodipine are:</p><p>- macrolide antibiotics (e.g. erythromycin),</p><p>- anti-HIV protease inhibitors (e.g. ritonavir),</p><p>- azole antimycotics (e.g. ketoconazole),</p><p>- the antidepressants nefazodone and fluoxetine,</p><p>- quinupristin/dalfopristin,</p><p>- cimetidine,</p><p>- valproic acid.</p><p>Upon co-administration with these drugs, the blood pressure should be monitored and, if necessary, a reduction in the nimodipine dose should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nimotop tablets should not be administered concomitantly with Nimotop solution.</p><p><u>Drugs that affect nimodipine</u></p><p>Nimodipine is metabolised via the cytochrome P450 3A4 system, located both in the intestinal mucosa and in the liver. Drugs that are known to either inhibit or induce this enzyme system may, therefore, alter the first pass or the clearance of nimodipine (see section 4.2 &ndash; &nbsp;<em>&ldquo;Patients with hepatic impairment</em>).</p><p>The extent as well as the duration of interactions should be taken into account when administering nimodipine together with the following drugs:</p><p>The concomitant use of oral nimodipine and rifampicin or cytochrome P450 3A4 system-inducing antiepileptic drugs such as phenobarbital, phenytoin or carbamazepine is contraindicated (see section 4.3). The efficacy of Nimotop tablets could be reduced if these drugs are administered concomitantly.</p><p>Concurrent three times daily administration of 30mg nimodipine and three times daily administration of 10mg of the antidepressant nortriptyline to elderly patients resulted in a slight decrease in nimodipine plasma levels with no effect on nortriptyline plasma levels. The daily dose used in patients with subarachnoid haemorrhage is four times the daily dose used in this trial, thus the clinical significance of this interaction in the treatment of aneurysmal subarachnoid haemorrhage (aSAH) is uncertain.</p><p>Upon co-administration with the following inhibitors of the cytochrome P450 3A4 system the blood pressure should be monitored and, if necessary, an adaptation in the nimodipine dose should be considered (see section 4.2):</p><p>- macrolide antibiotics (e.g. erythromycin)</p><p>- anti-HIV protease inhibitors (e.g. ritonavir)</p><p>- azole anti-mycotics (e.g. ketoconazole)</p><p>- nefazodone</p><p>Although no formal interaction studies have been performed to investigate the potential interaction between nimodipine and these drugs the potential for drug interaction and increased nimodipine plasma concentrations cannot be excluded. (See section 4.4).</p><p>Azithromycin, although structurally related to the class of macrolide antibiotics, is void of CYP3A4 inhibition.</p><p>Concurrent twice daily administration of 30mg nimodipine and daily administration of 20mg of the antidepressant fluoxetine to elderly patients resulted in about 50% higher</p><p>nimodipine plasma levels, a marked reduction in fluoxetine levels, whilst its active metabolite norfluoxetine was not affected (see section 4.4).</p><p>The simultaneous administration of nimodipine with the anticonvulsant valproic acid or the H2-antagonist cimetidine can lead to an increase in the plasma concentration of nimodipine (see section 4.4).</p><p>Based on experience with the calcium-antagonist nifedipine, co-administration of quinupristin/dalfopristin may lead to increased plasma concentrations of nimodipine (see section 4.4).</p><p><u>Effects of nimodipine on other drugs</u></p><p>Animal studies have shown that when nimodipine and zidovudine are administered concomitantly, the AUC for zidovudine was increased, and the volume of distribution and clearance rate decreased. The clinical relevance of this interaction is unknown, but since the side-effects profile of zidovudine is known to be dose-related, this interaction should be considered in patients receiving nimodipine and zidovudine concomitantly.</p><p><u>Other types of interaction</u></p><p>Blood pressure lowering drugs</p><p>Nimodipine may increase the blood pressure lowering effect of concomitant antihypertensives, such as:</p><p>- diuretics,</p><p>- beta-blockers,</p><p>- ACE inhibitors,</p><p>- A1-antagonists,</p><p>- other calcium antagonists,</p><p>- alpha-adrenergic blocking agents,</p><p>- PDE5 inhibitors</p><p>- alpha-methyldopa.</p><p>However, if a combination of this type proves unavoidable particularly careful monitoring of the patient is necessary.</p><p>The intake of grapefruit juice is not recommended in combination with nimodipine as it can result in increased plasma nimodipine concentrations due to the inhibition of the oxidative metabolism of dihydropyridines. As a consequence, the blood pressure lowering effect may be increased. This effect may last for at least 4 days after the last ingestion of grapefruit juice.</p><p><u>Interactions shown not to exist</u></p><p>A study examining the effects of 90mg nimodipine (in divided doses) on elderly patients receiving haloperidol did not show evidence of potential interactions. It is unclear whether this study is relevant to use in subarachnoid haemorrhage because of the higher dose of nimodipine used.</p><p>Concomitant administration of oral nimodipine and diazepam, digoxin, glibenclamide, indometacin, ranitidine and warfarin did not reveal any potential for mutual interaction .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p>There are no adequate and well controlled studies in pregnant women. Reproductive toxicology studies in animals using oral administration showed no teratogenic effect,</p><p>although studies in animals have shown reproductive toxicity (see section 5.3). If nimodipine is to be administered during pregnancy, the benefits and potential risks must be carefully weighed according to the severity of the clinical picture.</p><p><u>Breast-feeding</u></p><p>Nimodipine and its metabolites have been shown to be present in human milk at concentrations of the same order of magnitude as corresponding maternal plasma concentrations. Nursing mothers are advised not to breast-feed when taking this drug.</p><p><u>Fertility</u></p><p>In single cases of in-vitro fertilisation calcium antagonists have been associated with reversible biochemical changes in the spermatozoa&#39;s head section that may result in impaired sperm function. The relevance of this finding in short-term treatment is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In theory, the possibility of the occurrence of the side-effect dizziness may impair the patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequencies of ADRs reported with nimodipine summarized in the tables below are based on clinical trials with nimodipine in the indication aSAH sorted by CIOMS III categories of frequency (placebo-controlled studies: nimodipine N = 703; placebo N = 692; uncontrolled studies: nimodipine N = 2496; status: 31 Aug 2005. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Frequencies are defined as:</p><p>Very common (&ge; 1/10),</p><p>Common (&ge; 1/100 to &lt; 1/10),</p><p>Uncommon (&ge; 1/1,000 to &le; 1/100),</p><p>Rare (&ge; 1/10,000 to &le; 1/1,000),</p><p>Very rare (&lt; 1/10,000)</p><table cellspacing="0" cellpadding="0" border="1" style="width:518.25pt"><tbody><tr><td style="vertical-align:top; width:40.0%"><p><strong>System Organ Class</strong></p><p><strong>(MedDRA) </strong></p></td><td style="vertical-align:top; width:30.0%"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:30.0%"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Blood and the lymphatic system disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Thrombocytopenia</p></td><td style="vertical-align:top; width:30.0%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Immune system disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Allergic reaction</p><p>Rash</p></td><td style="vertical-align:top; width:30.0%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Headache</p></td><td style="vertical-align:top; width:30.0%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Tachycardia</p></td><td style="vertical-align:top; width:30.0%"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Vascular disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Hypotension</p><p>Vasodilatation</p></td><td style="vertical-align:top; width:30.0%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:30.0%"><p>Nausea</p></td><td style="vertical-align:top; width:30.0%"><p>Ileus</p></td></tr><tr><td style="vertical-align:top; width:40.0%"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:30.0%">&nbsp;</td><td style="vertical-align:top; width:30.0%"><p>Transient increase in liver enzymes</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA call center: 19999.</p><p>E - mail: npc.drug@sfda.gov.sa.</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms of intoxication</u></p><p>Symptoms of acute overdosage to be anticipated are marked lowering of the blood pressure, tachycardia, bradycardia and (after oral administration) gastro-intestinal complaints and nausea.</p><p><u>Treatment of intoxication</u></p><p>In the event of acute overdosage, treatment with Nimotop must be discontinued immediately. Emergency measures should be governed by the symptoms. Gastric lavage with addition of charcoal should be considered as an emergency therapeutic measure. If there is a marked fall in blood pressure, dopamine or noradrenaline can be administered intravenously. As no specific antidote is known, subsequent treatment for other side effects should be aimed at the most prominent symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: selective calcium channel blockers with mainly vascular effect, dihydropyridine derivatives, ATC Code: C08CA06</p><p>Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels.</p><p>Vasoconstrictions provoked <em>in vitro</em> by various vasoactive substances (<em>e.g.,</em> serotonin, prostaglandins and histamine) or by blood and blood degradation products can be prevented or reduced by up to 75 % by nimodipine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The intravenous Nimotop solution is 100 % available to the tissues as the peripheral venous blood takes the drug to the lungs and heart and from there to all organs.</p><p><u>Absorption</u></p><p>After oral ingestion, absorption is rapid. Peak plasma concentrations are observed 30 to 60 minutes following oral administration. Despite high gastrointestinal absorption of nimodipine, the absolute bioavailability is 5 &ndash; 15 %, which is attributed to extensive first pass metabolism (about 85 &ndash; 95 %).</p><p><u>Distribution</u></p><p>The distribution volume (Vss, 2 compartment model) for i.v. administration is calculated to be 0.9 &ndash; 2.3 l/kg body weight. The total (systemic) clearance is 0.8 &ndash; 1.6 l/h/kg. Nimodipine is 97 &ndash; 99 % bound to plasma proteins.</p><p><u>Biotransformation</u></p><p>The cytochrome P450 3A4 system plays a major role in the metabolic elimination of nimodipine. Nimodipine is eliminated as metabolites, mainly by dehydrogenation of the dihydropyridine ring and oxidative O-demethylation. Oxidative ester cleavage, hydroxylation of the 2- and 6-methyl groups, and glucuronidation as a conjugation reaction are other important metabolic steps. The three primary metabolites occurring in plasma show no or only therapeutically negligible residual activity.</p><p><u>Elimination</u></p><p>Effects on liver enzymes by induction or inhibition are unknown. In humans the metabolites are excreted about 50% renally and 30% in the bile</p><p><u>Linearity/non-linearity</u></p><p>For oral administration, the peak plasma concentration and the area under the curve increase proportionally to the dose up to the highest dose under test (90 mg). The elimination kinetics are linear. The half-life for nimodipine is between 1.1 and 1.7 hours. The terminal half-life is 5-10 hours, and is not relevant for establishing the recommended dosing interval for the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction. However, several preclinical findings may be of relevance to the prescribing physician. In chronic repeat dose toxicity studies in dogs, doses of 1 and 2.5 mg/kg/day were shown to be tolerated without adverse effect. However, at the higher dose of 6.25 mg/kg/day significant changes in ECGs were noted due to disturbances in myocardial blood flow, but there was no indication of histopathological damage to the heart. In pregnant rats, doses of 30 mg/kg/day and higher inhibited fetal growth and resulted in reduced fetal weights. At 100 mg/kg/day embryolethality occurred. No evidence of teratogenicity was observed. In rabbits, equivocal evidence of teratogenicity was seen in one study at doses up to 10 mg/kg/day. In two subsequent studies (one at 30 mg/kg/day), these findings were not reproduced. In one peri-postnatal study in rats, mortality and delayed physical development were observed at doses of 10 mg/kg/day and higher. The findings were not confirmed in subsequent studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, maize starch, povidone, crospovidone, magnesium stearate, hypromellose, macrogol 4000, titanium dioxide E171, iron oxide yellow E172.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PP/aluminium blister packs contained in cardboard outer, containing 100 x 30mg tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG,
51368 Leverkusen
Germany.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>